To this end, CRISPR Therapeutics is currently managing five other clinical trials, with several more pre-clinical studies ...

“We have demonstrated, for the first time worldwide, that CRISPR-Cas9 can be used to incorporate a desired sequence into ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

CRISPR Therapeutics benefits from Casgevy’s approval and a deep pipeline, despite early rollout hurdles and cost challenges.

CRISPR technique boosts nitrogen fixation in beans, reduces fertilizer use, and supports sustainable farming for a better ...

A study of human tumor cells implanted in mice from the MacPherson Lab at Fred Hutch describes a new way to screen for the ...

The country's third most valuable company by market cap is a study in contrasts. It's a wealth-altering 13-bagger over the ...

Fyodor Urnov and Kiran Musunuru advocate for streamlined CRISPR treatments for rare genetic diseases, partnering with Danaher ...

The University of Bayreuth's Biomaterials research group has, for the first time, successfully applied the CRISPR-Cas9 ...

CRISPR Therapeutics, whose CEO is Samarth Kulkarni, and Vertex Pharmaceuticals earned the first U.S. Food and Drug ...

CRISPR Therapeutics faces challenges with a 20% stock drop, slow Casgevy commercialization, and regulatory hurdles. Read more ...